Bo Cumbo, new Solid Bio CEO
September 30, 2022 07:45 AM EDTUpdated 04:51 PM
Deals
Cell/Gene Tx

Sol­id Bio gets a new CEO, $75M cash and drops lead drug as big in­vestors ju­ry-rig a merg­er deal

John Carroll

Editor & Founder

Three months af­ter End­points News broke the sto­ry that gene ther­a­py out­fit Aa­van­tiBio had gut­ted its CMC group in a re­or­ga­ni­za­tion, the biotech’s CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times